The United States Food and Drug Administration (FDA) authorizes one dose of the COVID vaccine from Johnson & Johnson, the third in the United States.

The U.S. Food and Drug Administration has authorized a third COVID-19 vaccine for public use, and as expected on Saturday, Acting Commissioner Dr. Janet Woodcock granted emergency use permission for a vaccine developed by Janssen Pharmaceuticals, Johnson & Johnson. About 4 million doses of the new vaccine are scheduled to be available next week, 20 million in total during March, and another 80 million by the end of June. Because the vaccine requires only one dose, it will help protect 100 million people and take effect more quickly than the two vaccines, and the J&J vaccine joins two others, one from Pfizer-BioNTech and the other from Moderna, who have been given to nearly 50 million Americans since it was They were authorized in December. Do you want a hug again? “It’s up to you”: A new advertising campaign gets to the point about COVID-19 vaccines – An advisory panel from the Food and Drug Administration voted Friday to support the J&J vaccine, finding that its benefits far outweigh its risks. Woodock agreed. “Licensing this vaccine broadens the scope of this vaccine,” Woodcock said in a statement: “Vaccines provide, the best medical prevention for COVID-19, to help us fight this pandemic, which has killed more than half a million people in the United States.” The Food and Drug Administration has permitted, Through our open and transparent scientific review process, three COVID-19 vaccines with the urgency required during this pandemic, using the agency’s stringent standards of safety, efficacy, and manufacturing quality needed to support licensing of emergency use. ”President Joe Biden said in a statement that Saturday’s statement means“ having Light at the end of the tunnel “But he stressed again the importance of mitigation measures such as hand washing and social distancing. And he said,” We know that the more people who get vaccinated, the faster the virus can be overcome, return to our friends and loved ones, and put our economy back on track. ” “This battle is not over yet,” he added. Although we’re celebrating the news of the day, I urge all Americans – keep washing your hands, stay socially distant, and keep wearing masks. As I’ve said many times, things are still likely to get worse as new variables proliferate, and the current improvement may lead to the opposite. ”Richard Pesser, President and CEO of the Robert Wood Johnson Foundation and former Acting Director of the Centers for Disease Control and Prevention, praised the Food Administration’s decision. Medicine, but he cautioned against laxity. ” With three vaccines for COVID-19 now available, the number of cases and deaths still falling across the country, and Congress taking steps toward approving much-needed additional economic relief, I have never felt encouraged that we might begin Finally this epidemic. ”Pesser also said that increases in vaccine supply“ are welcome but not sufficient on their own to end “racial disparities in vaccine distribution.” People of color in the United States have suffered a dire dichotomy: among the highest rates of COVID-19 cases, hospitalizations and deaths, and among the lowest vaccination rates. ”Moderna and Pfizer-BioNTech appear to be more effective than J & J, as they have shown better efficacy than 94% in the large trials conducted last year, although it could not be directly compared, because the trials were conducted at different times, the J&J vaccine appeared to be 72% effective among participants in the US trials. It was less effective in South Africa. And Latin America, where new strains of the virus are spreading, and the side effects of the COVID-19 vaccine could mimic a sign of breast cancer: This is normal, doctors say.Distribution should also be easier in rural areas and other places without grade freezers. Pharmaceutical-grade, because it can be stored for longer in the refrigerator, and may cause fewer side effects than the other two vaccines, as only about half of the trial participants reported injection site pain compared to nearly 80% of the Pfizer-BioNTech and Moderna vaccines, especially with the second vaccines. Committee a A CDC consultant on Sunday and Monday discussing how to use the J&J vaccine. The vaccine will be reviewed by Dr. Rochelle Wallinski, head of the CDC, and it should be ready for distribution early next week. Contact Karen Weintraub at [email protected]. Grant from the Massimo Foundation for Ethics, Innovation, and Competition in Healthcare. The Masimo Foundation does not provide editorial input.